Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.04.2023 | Case report

Gefitinib/osimertinib

Various toxicities and lack of efficacy: 3 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Shoji S, et al. Three non-small cell lung cancer patients who developed pulmonary thromboses during osimertinib treatment and could safely resume concomitant anticoagulation treatment: a report of three cases. Translational Lung Cancer Research 11 : 2601-2607, No. 12, Dec 2022. Available from: URL: http://doi.org/10.21037/tlcr-22-419 Shoji S, et al. Three non-small cell lung cancer patients who developed pulmonary thromboses during osimertinib treatment and could safely resume concomitant anticoagulation treatment: a report of three cases. Translational Lung Cancer Research 11 : 2601-2607, No. 12, Dec 2022. Available from: URL: http://​doi.​org/​10.​21037/​tlcr-22-419
Metadaten
Titel
Gefitinib/osimertinib
Various toxicities and lack of efficacy: 3 case reports
Publikationsdatum
01.04.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-36599-2

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Iron

Case report

Multiple drugs

Case report

Rucaparib